Israeli company BioCancell Therapeutics Ltd., has announced positive results in a Phase IIb clinical trial of its BC-819 treatment for pancreatic cancer. The study showed that the drug is safe for all patients and that increasing the dosage of the drug does not cause deterioration in the patients’ condition.
Related posts
UN Honors Israeli Food Exec For Sustainability Work
September 26, 2023
Startup Unveils Tech To Speed Up Growth Of Cultivated Meat
September 26, 2023
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Facebook comments